FibroBiologics receives Nasdaq MVLS deficiency notice; 180-day cure period to Feb 2026

FibroBiologics, Inc.

Nasdaq notified FibroBiologics on Aug 4, 2025 that its MVLS fell below the $35M minimum for continued listing.
Company has until Feb 2, 2026 to regain compliance by having MVLS close at $35M+ for 10 consecutive business days.
No immediate impact on listing; stock continues trading on Nasdaq Capital Market under symbol FBLG.
If compliance is not regained by Feb 2, 2026, Nasdaq may initiate delisting, subject to appeal.
Company will monitor MVLS and consider available options to address the deficiency.

item 3.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.